

# Eczema Titbits

The Maiden Voyage

Society for Eczema Studies (https://eczemasociety.net)

Volume 1; Issue 1; March 2023

### **SES Executive Committee**

#### President

Dr Sandipan Dhar

### **Vice President**

Dr Manjunath Shenoy M

### **Hony. Secretary**

Dr Raghubir Banerjee

### **Treasurer**

Dr Rajib Malakar

### **Jt. Secretaries**

Dr Maitreyee Panda

Dr Soumya Jagadeesan

Chairperson, SES Academy

Dr Deepika Pandhi

**Convener, SES Academy** 

# Dr Dipankar De

### Dr Manjunath Shenoy M Editor-In-Chief



pen my thought as the editor in chief of the bulletin of Society is a matter of privilege provided to me by

our President Dr Sandipan Dhar. The first issue highlights activities that the society has accomplished in the past 1 year. A year full of top-class academics and icing on the cake is the SESNATCON, the National Conference. International and national physical and virtual CMEs enriched the viewers and changed the way we manage eczemas. The bulletin also has some brain teasing journal update, quiz, crosswords etc. that will enthrall the readers.

I immensely thank the entire editorial committee for their tireless work due to which we could launch this bulletin within 15 days.

Long live SES.



## **Dr Sandipan Dhar**

President, Society For Eczema Studies (SES)

t gives me great pleasure to write this message for first issue of the SES bulletin. This is a dynamic endeavor under the leadership of Dr Manjunath Shenoy (Editor) supported by Dr Indrashis Poddar (executive editor), Dr Sahana Srihari and Dr Sahana P Raju (associate editors). I sincerely congratulate and thank them all for taking up this

challenging job. I am sure all the members, would be members and non members will benefit from this bulletin in which lots brainstorming, ideas, new thoughts, directions and dimensions on "eczema" have been integrated.

Happy reading!

Long live SES



# Dr Deepika Pandhi

Chairperson, Academy, SES

he Society for Eczema Studies, initiated in 2022, has in its first year attempted to put in the spotlight the various aspects of Eczema, through focused physical and virtual CME programs, that have included national and international experts and a standalone conference in December 2022. With a focus on generating data pertaining to Eczema from India. Another key focus has been on research, with initiation of a multicentric study on Pediatric Atopic Dermatitis epidemiology and 3 postgraduate thesis grants of up to one lakh each in its inception year. There are several more exciting research studies planned in Atopic dermatitis and beyond and we have partnered with the Skin Allergy Research Society to bring out a journal "Indian Journal of Skin Allergies", that would encourage research in this often ignored sub

domain of dermatology. We hope you will stay tuned and participate in the upcoming SES activities and also contribute and strengthen the journal.

Hope to interact in the near future

### **Editorial Board**

**Editorial Advisor** Dr Sandipan Dhar

**Editor-In-Chief** 

Dr Manjunath Shenoy M

**Executive Editor** 

Dr Indrashis Poddar

**Associate Editors** 

Dr Sahana Srihari

Dr Sahana P Raju

### **Editorial Committee Members**

Dr Deepika Pandhi

Dr Dipankar De

Dr Abhijith Saha

**SES New Bulletin** Vol 1; Issue 1: Mar 2023



ociety for Eczema Studies (SES) is one of its kind, dream project by Dr Sandipan Dhar, a consortium of passionate Indian and International

Shenoy is concocted with details of the various activities by SES, eczema titbits and has an enthralling crossword and quiz. Highlights of some of the best articles on eczemas will also be part of this bulletin. All this has been possible only due to the hard work put in by the entire editorial team and the SES team. all of you.

















# **PHYSICAL LAUNCH IN INDIA DELHI**









SES New Bulletin Vol 1; Issue 1: Mar 2023

# "E-LEARNING DOESN'T JUST "HAPPEN"

IT REQUIRES CAREFUL●
PLANNING AND IMPLEMENTATION"






mastermind of Dr Sandipan Dhar successfully had series of WEBINARS on various aspects of Atopic Dermatitis and its treatment including moderators and speakers all over our country and abroad

- 1 Impacts of new treatments on comorbidities of atopic dermatitis
- 2 Atopic dermatitis in Covid Era
- 3 Microbiome of skin and role of probiotics in atopic dermatitis
- 4 Atopic March
- 5 Long term systemic complication of AD- From disease its treatment
- 6 Menace of topical steroid abuse in India- where do we stand
- 7 Cyclosporine in dermatology
- 8 Judicious use of topical steroids in managing AD- A paradigm shift
- 9 Drug reaction in atopic dermatitis

















### Message from International Advisory Board Members



Thank you very much for your invitation, of course I accept as I am honoured.
- Dr Paula C Luna, Argentina



Many thanks for the kind invitation. It is my honour to accept the invitation and I hope to be able to contribute to the society as best I can- Dr Mark Koh, Singapore



Thank you so much. Happy to join SES, the first of its kind in South East Asia. With every best wish, Dr Alan Irvine, Ireland



Thank you for inviting me; It is an honor to be part of the Society. Thank you once again. Dr Tay Yong Kawang, Singapore



Very happy to join this SES, a dedicated society on eczema from Eastern part of the globe.

Dr Robert Sidbury, USA



Fantastic vision of yours to start the society dedicated to the subject of eczema. West has very little idea about AD and other eczemas from your part of the world - Dr Nick Reynolds, UK



Wow! what a great thought to establish the society.

Congratulations! Happy to be a part of it

Dr Emma Guttmann Yasski, USA



Thanks for the invitation. SES has a great future. Happy to be on board Dr Amy Paller, USA



Great Society, great leadership. Happy to join SES
- Dr Jacob P Thyssen, Denmark



We will make this endeavor of yours globally popular.
Way to go....SES
- Dr Christian Vestergaard, Denmark



Thanks for the invite to join the society dedicated to eczema. Feel honored to join - Dr Kenji Kabashima, Japan **SES New Bulletin** Vol 1; Issue 1: Mar 2023

### COMMEMORATION OF WORLD **ATOPIC DERMATITIS DAY**



14TH SEPTEMBER 2022 **DEHRADUN** (THE CITY OF LOVE)









### Gala feast of science! with

Dr. Tarun Mittal Dr. B S Judge Dr. Vijay Bakaya Dr. Abir Saraswat Dr. Rashmi Jindal

### **Inaugural SES Thesis Grant Awardees**

- A cross sectional study of the comparative effectiveness of Hanifin Rajka Criteria vs. UK Working Party Criteria in diagnosis Pediatric Atopic Dermatitis and severity assessment PG Student: Dr Asritha CVV Guide: Dr Maitreyee Panda Institute of Medical Sciences and SUM Hospital, Bhubaneshwar
- Assessment of clinical phenotypes and endotypes in a cohort of adult patients having atopic dermatitis PG Student: Dr Manavi Gupta Guide: Dr Anuradha Bishnoi PGIME&R, Chandigarh
- ♦ Measurement of serum TSLP in pediatric atopic dermatitis patients and its association with disease severity PG Student: Dr Neenu Prasad Guide: Dr Sreedevan Amrita Institute of Medical Sciences, Kochi

### THEME 'ATOPIC DERMATITIS: INDIAN PERSPECTIVES'

- 1. Clinical presentations of AD in skin of colour- Dr Sahana Srihari
- 2. Topical therapy- what we do to patients Dr Manjunath Shenoy
- 3. Systemic therapy- from bench to bedside- Dr Vikrant Saoji
- 4. Open house panel discussion/audience interaction- Dr. Rajeev Sharma





Dr Sahana P Raju Associate Editor

t gives me immense joy and great pleasure to work as the Associate editor of the bulletin of SES (Society of Eczema Studies). I am grateful to Dr. Sandipan Dhar, the President of SES and Dr. Manjunath Shenoy, the editor - in-chief for giving me this wonderful opportunity of working alongside with them. SES was created with the main purpose of creating awareness regarding eczemas, especially in skin of color, worldwide. In this bulletin, we have tried to incorporate the essence of SES, along with a touch of fun, which will require some amount of brainstorming from our readers.

I am extremely thankful to the entire editorial team for burning the midnight oil and coming up with this wonderful bulletin.

Do join SES and join us on this wonderful journey! Long live SES!

### NATIONAL SYMPOSIUM FOR PEDIATRIC ALLERGY

27<sup>th</sup> November, 2022

in association with local dermatology and pediatrics associations of Mangalore.





Dr Sandipan Dhar and Brig. Dr Manas Chatterjee along with more than 15 dermatology and pediatrics faculties discussed on various aspects of pediatric allergies. Dr Manjunath Shenoy along with faculties of departments of dermatology and pediatrics hosted this symposium in the Yenepoya Medical College, Mangalore.

SES New Bulletin Vol 1; Issue 1: Mar 2023



t is my absolute pleasure and privilege to be appointed the Executive editor of the bulletin of the Society for Eczema studies (SES). This society is the brain child of visionary Dr. Sandipan Dhar, and the main objective is to spread awareness about various allergic skin disorders among both treating physicians and patients. This is very much needed, as allergic diseases are increasing all over the globe, including India, and is being hailed the next 'pandemic'. This bulletin aims to appraise physicians about the works conducted by the SES and its future

I profusely thank the entire editorial committee for their hard work to make this bulletin a reality. We have tried to make this bulletin interesting by including quiz, crosswords for readers benefit. A separate section is introduced 'Editor's picks' which will highlight few recent and pathbreaking articles in this

Enjoy reading and become a part of the SES movement! Long live SES!

# ATOPIC


- 1. Allergy tests, such as skin prick tests and blood tests are very useful diagnosing the cause of atopic eczema
- a. True
- False
- 2. Which of the following is NOT a part of the UK Working group diagnostic criteria for Atopic Dermatitis?
- a. Generalized pruritus
- b. Personal or family history of atopy
- c. Visible or history of flexural dermatitis
- d. Onset under 5 years age
- 3. What is the maximum SCORAD (SCOring Atopic Dermatitis) score?
- a) 83
- b) 93
- c) 103
- d)
- 4. Crisaborole is a recent topical medication approved for treating mildmoderate atopic dermatitis in children and adults. It is an inhibitor of which enzyme?
- JAK1
- b. JAK1+JAK2
- c. PDE3
- d. PDE4
- 5. What is the minimum age approved for the use of Dupilumab in Atopic Dermatitis
- a. 6 months
- b. 5 years
- 12 years C.
- 18 years

### Answers-

1-b, 2-d, 3-c, 4-d, 5-a

### Editor's Picks

- This section will provide an idea about the most interesting aspects of an allergic skin condition published recently in the literature. Going through these articles will help you stay updated with latest happenings in this field. Happy reading!
- Mosam A, Todd G. Global epidemiology and disparities in atopic dermatitis. Br J Dermatol. 2023 Mar 7:ljad042. [Epub ahead of print]. PMID: 36881991.
  - O This Review article describes the global epidemiology and disparities that exist in various populations and regions across the globe. Inequities in access to healthcare and the quality of healthcare provided amongst racial and ethnic minority groups is well documented.
- Abolhasani R, Araghi F, Tabary M, Aryannejad A, Mashinchi B, Robati RM. The impact of air pollution on skin and related disorders: A comprehensive review. Dermatol Ther. 2021;34:e14840. doi: 10.1111/dth.14840. Epub 2021 Feb 12. PMID: 33527709.
  - Recently air pollution is being considered a risk-factor for AD, linked to epidermal barrier defects. Studies exist in heterogeneous populations with varying results. This article reviews recent studies on the correlation between air pollutants and skin diseases, along with related mechanisms
- Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021 Apr 16;22(8):4130. doi: 10.3390/ijms22084130. PMID: 33923629; PMCID: PMC8074061.
  - $\Diamond$  This article provides an overview about the recent understandings concerning the molecular mechanisms of Atopic Dermatitis and their implications on management. There are lucid diagrams which would help provide clarity to the reader.
- Villa-Gonzalez JM, Gonzalez-Hermosa MR, Gardeazabal García J, Aramburu González A, Orbea Sopeña A, Pascual Ares M et al. When the cure becomes worse than the disease: a case series of children with allergic contact dermatitis from chlorhexidine. J Eur Acad Dermatol Venereol. 2023 Mar 13. doi: 10.1111/jdv.19034. [Epub ahead of print] PMID: 36913262.
  - ♦ This interesting paper depicts the allergenic potential of chlorhexidine in children, one of the most widely used antiseptics in our set-up.



#### ACROSS:

- 3 Arachis hypogaea! I am nuts, I can trouble you, at times even kill you o child! (7) 6 - A naturally occurring compound found in bacterial symbionts of nematodes which also has antibiotic properties. Smear me on, I shall help you with my aryl hydrocarbon receptor modulating properties. (9)
- 7- Highly reduced microgametophytes. You inhale me, I trouble you! (6)
- 10 Substances that, after induction into the skin, elicits both the sensation of itch and an urge to scratch. (11)
- 11 French physician who in 1892 described dermatitis multiformis pruriginosa and first recognized the link to hay fever and allergic asthma. (7)
- 15 I am a wonderful immunomodulating agent, I help and treat your dermatitis beautifully but am stuck with a 'black box warning' not very rightly! Im sad....Expensive though! (12)
- 17 I love the bones, you pull me into skin and hair. I inhibit a family of intracellular, non- receptor tyrosine kinases that transduce cytokine-mediated signals. Be Careful, get me approved (11)
- 18 I am modified sun, I help everyone from neonates to very old age in varying situations. Protect your eyes and genitals though! (12) 19 – I am caused by opportunistic bacteria that prolong healing and may cause serious scarring and morbidities (15)

- 1 I am made from parts of living organisms. I am a monoclonal antibody and block interleukin 4 and interleukin 13. I help you but beware I could get red eyed and angry too! (9)
- 2 Half of my word is a protein and the other half means I assemble. You can see me through light microscopy. If my function is reduced, I can welcome allergens into and affect your skin and lungs! (9)
- 4 Increased sensitivity to itch to previously non-itchy stimuli. Name me... (11) 5 I am an invisible process, individual or small groups of cute little us detach from each other to be lost to the environment and replaced by younger versions of ourselves from the deeper layers (16) 8 - Ek main aur ek tu! Us ek ko  $1/3^{rd}$  kardo, wahan se yahaan tak. Measure karo, squeeze the medication on, calculate
- calculate and apply... (3)
- 9 First they thought I am expressed by leukocytes but I am produced by many cells! Iplay essential roles in the activation and differentiation of immune cells, as well as proliferation, maturation, migration, and adhesion. Name me? (12)

  12 – A semi-solid mixture of hydrocarbons, Do I sound complicated? Open your shelf, I am right there. I am needed to a
- great extent but the European Union dassified me as a carcinogen! I am not allowed in cosmetic products (10)
- 13 Urticaria factitial. Just because I show when you scratch, do you think I am a board and you can write on me?? (13) 14 I have been recently approved by the FDA for treating refractory atopic dermatitis. A second generation Janus kinase inhibitor that is selective for the JAK1 subtype of the enzyme over the JAK2 (12)
- 16 Oil made from me can boost the skin's ability to make ceramide fats (fats essential for skin hydration and improved skin barrier). I am beautiful and I thrive in environments where I can receive six or more hours of direct sunlight (9)

12-PETROLATUM; 13-DERMOGRAPHISM; 14-UPADACITINIB; 16-SUNFLOWER Down: 1-DUPILUMAB; 2-FILAGGRIN; 4-ALLOKINESIS; 5-CORNEODESMOLYSIS; 8-FTU; 9-INTERLEUKINS; 18-РНОТОТНЕВАРУ; 19-5 ПРЕВІМ ГЕСТІОИS ACTOSS: 3- PEANUTS; 6-TAPINAROF; 7-POLLEN; 10-PRURITOGENS; 11-BESNIER; 15-PIMECROLIMUS; 17-TOFACITINIB; SES New Bulletin Vol 1; Issue 1: Mar 2023



The SES, envisioned and effectuated by Dr. Sandipan Dhar, conducted it's first national conference (SESNatCon) on the 17th and 18th of December in the charming city of Kolkata. The conference was a powerhouse of knowledge and expertise, with eminent dermatologists from across the country coming together to share their experience in the field of eczema. The academic sessions included recent trends in atopic dermatitis in skin of color, current perspectives, newer therapeutic agents and research reports. Additionally, thesis grants of Rs. 1 lac each was awarded to 3 candidates for topics related to eczema research.





One of the highlights of the conference was the mind boggling grand finale of the SES quiz; which was one of a kind where a practising dermatologist was teamed with a resident dermatologist.











The global journey of SES, with a message of creating awareness about atopic dermatitis, was flagged off in the charming city of Dhaka, Bangladesh coupled with the 4th International conference on Psoriasis and Inflammatory Skin Disorders, in collaboration with SPIN, Paris. There were more than 650 delegates, with Professor Samiul Huq leading from the front.

The SES launch in Kathmandu was another grand success with over 150 delegates, headed by Dr. Anil K Jha. SES was also specially highlighted during the 1st immunodermatology update held in Kuwait. Dr. Sandipan's talk captured the attention of all those present, including the president of the Kuwaiti dermatology society, Dr. Mohammed Alotaibi.